Insilico Medicine Advances AI-Discovered Drug for IPF to Phase III Trials

Insilico Medicine has initiated Phase III clinical trials for rentosertib, an AI-discovered and designed drug targeting idiopathic pulmonary fibrosis (IPF), marking a pivotal moment for computational drug discovery. This advancement positions rentosertib as potentially the first AI-originated "foundation-stage" drug candidate to reach late-stage human trials, offering crucial empirical validation for the burgeoning AI-driven pharmaceutical sector.

Rentosertib, previously known as ISM001-055 or INS018_055, is a first-in-class small molecule designed to inhibit TNIK (TRAF2- and NCK-interacting kinase), a novel anti-fibrotic target identified by Insilico's proprietary Pharma.AI platform. The drug's journey from target identification to preclinical candidate took under 18 months, a significantly accelerated timeline compared to traditional methods. Encouraging Phase IIa data, published in *Nature Medicine*, demonstrated manageable safety and tolerability, with patients receiving the 60 mg once-daily dose showing a mean increase of 98.4 mL in forced vital capacity (FVC) after 12 weeks, against a 20.3 mL decline in the placebo group.

This progression carries profound implications. IPF is a devastating, age-related fibrotic lung disease with a grim prognosis and limited treatment options; existing antifibrotic drugs like pirfenidone and nintedanib only slow progression and often come with challenging side effects. Rentosertib, with its novel mechanism and aging-informed approach, could represent a much-needed disease-modifying therapy. The global Phase III trial will enroll 1,200 patients across 180 sites in North America, Europe, and Asia, with a primary endpoint of annualised FVC decline over 52 weeks and a topline readout targeted for Q3 2027.

While AI has already proven its ability to accelerate early-stage drug discovery, significantly reducing timelines and improving Phase I success rates, Phase III remains the ultimate crucible for efficacy. Rentosertib's success or failure in this demanding stage will not only shape Insilico Medicine's future but also profoundly influence investor confidence and the broader adoption of AI across the entire pharmaceutical development pipeline. The industry watches closely as AI’s promise moves from computation to definitive clinical outcomes.

Watch (Shorts)